DFO
KITE

Duquesne Family Office’s Kite Pharma, Inc. KITE Stock Holding History

Duquesne Family Office’s Portfolio KITE Stock Details KITE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q4 		– Sell
-40,000
Closed -$1.14M – 51
2014
Q3 		$1.14M Buy
+40,000
New +$990K 0.14% 35

Other funds holding KITE

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
WCM
Wildcat Capital Management New York $106M AUM 0.1% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
JMPWA
JP Morgan Private Wealth Advisors San Francisco, California $35B AUM 24.26% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
SFM
Soros Fund Management New York $9.12B AUM 30.69% 1-Year Est. Return

Duquesne Family Office's KITE Position: Q4 2014 in Review

Duquesne Family Office sold out of Kite Pharma, Inc. (KITE) in Q4 2014, closing a stake of 40,000 shares — an estimated $1.14M sold.

Duquesne Family Office first reported a position in KITE in Q3 2014 and held it in 1 quarter. The position peaked at $1.14M in Q3 2014. 116 funds tracked by Wall St. Rank hold KITE as of Q4 2014.

  • Duquesne Family Office reported no remaining Kite Pharma, Inc. position as of Q4 2014 after selling out during the quarter.
  • Duquesne Family Office sold 40,000 Kite Pharma, Inc. shares in Q4 2014, an estimated $1.14M.
  • Duquesne Family Office first reported a position in Kite Pharma, Inc. in Q3 2014 and held it in 1 quarter.
  • Duquesne Family Office's Kite Pharma, Inc. position peaked at $1.14M in Q3 2014.
  • 116 funds tracked by Wall St. Rank held Kite Pharma, Inc. as of Q4 2014.

Based on Duquesne Family Office's 13F filing for Q4 2014, filed 12 Feb 2015.